General notice from NINDS:
[Improving the Quality of NINDS-Supported Preclinical and Clinical Research through Rigorous Study Design and Transparent Reporting ][1]
Some PARs/RFAs from NINDS:
*(PAR is Program Announcement with special receipt, referral and/or review considerations, as described in the PAR announcement)*
[NINDS Phase III Investigator-Initiated Efficacy Clinical Trials (U01)][2]
[NINDS Exploratory Clinical Trials (R01)][3]
[Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33) ][4]
General notice from NIDA:
[NIDA Notice: Improving Reporting of Research Methods and Results in Translational Addiction Research Involving Animals is a NIDA Commitment ][5]
NICHD PAR:
[Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities (R01)][6]
[1]: http://grants.nih.gov/grants/guide/notice-files/NOT-NS-11-023.html
[2]: http://grants.nih.gov/grants/guide/pa-files/PAR-13-278.html
[3]: http://grants.nih.gov/grants/guide/pa-files/PAR-13-281.html
[4]: http://grants.nih.gov/grants/guide/pa-files/PAR-15-070.html
[5]: http://grants.nih.gov/grants/guide/notice-files/NOT-DA-14-007.html
[6]: http://grants.nih.gov/grants/guide/pa-files/PAR-13-195.html